Author

Luca Lizzadro

University of California, San Francisco

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Biochemistry· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1 Organism:human· 1 Assay:proteomics· 1

Frequent Co-Authors

Adam R. RensloiD· 1 shared Alicia RichardsiD· 1 shared Amy DialloiD· 1 shared Annemarie F. CharvatiD· 1 shared Brian K. ShoichetiD· 1 shared Charles S. CraikiD· 1 shared Danielle L. SwaneyiD· 1 shared Dashiell Anderson· 1 shared

Activity by Year

2025-2025 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperBiochemistry

Adam R. RensloORCID

Mutual co-authors in cluster

Author profile →

1 paper

Recent·Most cited

Structure-based discovery of highly bioavailable, covalent, broad-spectrum coronavirus-MPro inhibitors with potent in vivo efficacy

Tyler C. Detomasi, Gilles Degotte, Sijie Huang, Rahul K. Suryawanshi, Amy Diallo, Luca Lizzadro, Francisco José Zapatero Belinchón, Taha Y. Taha, Jiapeng Li, Alicia Richards, Eric R. Hantz, Zain Alam, Mauricio Montaño, Maria McCavitt-Malvido, Rajesh Gumpena, , Charles S. Craik

This paper describes the discovery of new coronavirus MPro inhibitors with improved pharmacokinetics, broad-spectrum antiviral activity, and superior in vivo efficacy compared to existing drugs.

Science Advances · Apr 23, 2025Peer-reviewedBiochemistry